The Westchester Brain Tumor Program is offering a new testing option that could extend the life of patients suffering from complex brain tumors.
The testing, which profiles individual tumors at the molecular level, identifies biomarkers specific to an individual patient’s tumor and pinpoints the best treatment options.
“By comparing a patient’s tumor’s information with data from published clinical studies by thousands of the world’s leading cancer researchers, molecular testing can help identify potentially effect drugs, and eliminate ineffective treatments,” said Dr. John Abrahams, founder and director of the Westchester Brain Tumor Program. “This is a major step forward in our efforts to develop personalized cancer therapy.”
Molecular profiling testing is specifically recommended for patients with recurrent, complex brain tumors.
The Westchester Brain Tumor Program is collaboration between the Westchester Neuroscience Foundation, the Cancer Center at Northern Westchester Hospital, the Maria Fareri Children’s Hospital, and Brain & Spine Surgeons of New York.